Equol is an isoflavone (IF) metabolite produced by intestinal microbiota in a subset of people consuming dietary soy. Equol producers may show different responses to soy foods and phenotypes related to cancer risk. Here, we assessed the effects of soy IF, endogenous microbial equol production, and dietary racemic equol in a 3 3 2 3 2 factorial experiment using gnotobiotic apoE-null mice (n = 9-11/group/sex). At age 3-6 wk, equol-producing microbiota were introduced to onehalf of the colony (n = 122). At age 6 wk, mice were randomized to receive a diet that contained 1 of 3 protein sources:
Introduction
Epidemiological evidence has shown that the incidence of chronic diseases such as cancer and cardiovascular disease is lower in Asia than in Western countries. Lifestyle factors, including diet, have been identified as potential determinants (1,2). Soy-based foods rich in phytoestrogen isoflavones (IF) 7 are a primary component of many Asian but not Western diets (3). The intake of soy and the primary soy IF, genistein and daidzein, has been widely studied in association with cancer and other chronic diseases, but the results have been mixed and inconclusive (4). The lack of consensus regarding the health effects of soy IF interventions is due to a variety of potential factors, including variation in IF formulations across studies and interindividual differences in metabolism and response to soy diet (5).
Equol is a metabolite of daidzein produced by intestinal bacteria in ;30% of adult non-Asian and nonvegetarian populations consuming dietary soy protein (6,7). Approximately 10-30% are intermittent equol producers (8,9). Inter-individual variation in the ability to produce equol is a consequence of difference in gut microbial community. Several bacterial strains that can produce equol have been identified in vitro (10); however, the nature of the bacteria and how a person harbors them are incompletely understood. Factors such as dietary habit may modulate the composition and activity of gut microbes, hence affecting equol production (7). Recent evidence suggests that the ability to metabolize daidzein into equol may influence the health-related responses to soy exposure (11). However, it is unclear whether such effects are driven by equol directly or if equol production simply serves as a marker for other intestinal microbiota-mediated effects. Equol has distinct biological activity compared with daidzein and genistein. It binds to estrogen 
